KIR in Type 1 Diabetes
Disparate Distribution of Activating and Inhibitory Natural Killer Cell Receptors in Patients Versus HLA-Matched Control Subjects
- Arno R. van der Slik1,
- Bobby P.C. Koeleman12,
- Willem Verduijn1,
- G. Jan Bruining3,
- Bart O. Roep1 and
- Marius J. Giphart1
- 1Department of Immunohaematology & Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands
- 2Department of Medical Genetics, University Medical Center, Utrecht, the Netherlands
- 3Department of Clinical Genetics, Sophia Children’s Hospital, Erasmus Medical Center, Rotterdam, the Netherlands
- Address correspondence and reprint requests to Bart O. Roep, Department of Immunohaematology & Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands. E-mail: boroep{at}lumc.nl
Abstract
Killer cell immunoglobulin-like receptors (KIRs) modulate natural killer cell and T-cell function by interacting with HLA class 1 ligands on target cells. Both KIR and HLA are highly polymorphic. We studied the influence of KIR and HLA class 1 genes on the susceptibility to develop type 1 diabetes. The results showed increased numbers of activating KIR genes in patients compared with control subjects (P = 0.049). The combination of the activating KIR2DS2 gene, together with its putative HLA ligand, was present more frequently in patients than in diabetes high-risk HLA-matched control subjects (P = 0.030). Moreover, our results imply that an increase in activating KIR2DS2-HLA ligand pairs combined with a lack of inhibitory KIR-HLA ligand pairs is associated with an additional risk to develop type 1 diabetes in individuals with diabetes high-risk HLA alleles (P = 0.035). We propose that the genetic imbalance between KIR and their HLA class 1 ligands may enhance the activation of T-cells with a low affinity for pancreatic self-antigens, thereby contributing to the pathogenesis of type 1 diabetes.
Footnotes
-
Additional information for this article can be found in an online appendix at http://diabetes.diabetesjournals.org.
-
- Accepted July 16, 2003.
- Received May 12, 2003.
- DIABETES











